Retraction: MicroRNA-182 downregulates Wnt/&#x03B2;-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9

Zi-Feng Zhang; Yong-Jian Wang; Shao-Hua Fan; Shi-Xin Du; Xue-Dong Li; Dong-Mei Wu; Jun Lu; Yuan-Lin Zheng

doi:10.18632/oncotarget.28269

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Retraction:

Retraction: MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9

PDF | How to cite

Oncotarget. 2022; 13:1003-1003. https://doi.org/10.18632/oncotarget.28269

Metrics: PDF 706 views | ?

Zi-Feng Zhang^1,*, Yong-Jian Wang^1,*, Shao-Hua Fan¹, Shi-Xin Du², Xue-Dong Li², Dong-Mei Wu¹, Jun Lu¹ and Yuan-Lin Zheng¹

¹Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou 221116, P.R. China
²Department of Orthopedics, The Third Affiliated Hospital, Shenzhen University, Shenzhen 518002, P.R. China
^*Co-first authors

Published: September 06, 2022

Copyright: © 2022 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: In July of 2020, the Academic Committee of Jiangsu Normal University launched an investigation of this paper and requested that the major authors provide the original experimental records and data for verification. To date, however, the authors have failed to provide the requested documents. The committee has concluded that this paper violates academic integrity. In light of this, the paper is retracted.

Original article: Oncotarget. 2017; 8:101345–101361. DOI: https://doi.org/10.18632/oncotarget.21167.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28269

Publication Alerts

Retraction:

Retraction: MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9